<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642135</url>
  </required_header>
  <id_info>
    <org_study_id>P050308</org_study_id>
    <secondary_id>réf Afssaps : 437-050883-LB/GG</secondary_id>
    <secondary_id>Eudract : 2005-004418-33</secondary_id>
    <nct_id>NCT00642135</nct_id>
  </id_info>
  <brief_title>CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment</brief_title>
  <official_title>Efficacy and Tolerance of Ophthalmic Insert Mydriasert® Versus Reference Treatment (Phenylephrine and Tropicamide Eyedrops) in Premature Newborns, Neonates and Infants Justifying a Mydriasis for a Bilateral Diagnosis Fundus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ioltech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pupillary dilation to perform a fundus in premature newborns and neonates is often difficult
      to obtain, because of the non mature iris sphincter. The fundus is essential to detect
      retinal anomalies (as retinopathy of prematurity or chorioretinal or disk anomalies). The aim
      of the study is to obtain a satisfactory degree of mydriasis with a minimal dose of two
      mydriatic treatments, with an optimal duration and a good tolerance of the drugs. The study
      will evaluate the mydriasis in premature newborns, neonates and infants justifying a
      mydriasis for a bilateral diagnosis fundus, using ophthalmic insert Mydriasert® versus
      reference treatment (association of phenylephrine and tropicamide eyedrops). Ophthalmic
      insert Mydriasert® can control drug dispensation and decrease the number of nurse
      interventions to obtain mydriasis in patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to obtain a satisfactory degree of mydriasis with a minimal dose of
      two mydriatic treatments, with an optimal duration and a good tolerance of the drugs. The
      study will evaluate the mydriasis in premature newborns, neonates and infants justifying a
      mydriasis for a bilateral diagnosis fundus, using ophthalmic insert Mydriasert® versus
      reference treatment (association of phenylephrine and tropicamide eyedrops). Ophthalmic
      insert Mydriasert® can control drug dispensation and decrease the number of nurse
      interventions to obtain mydriasis in patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The total number of patients has been reached.
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <primary_completion_date type="Anticipated">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mydriasis larger than 5,5 mm with absence of photometer reflex to get a satisfactory fundus.</measure>
    <time_frame>75 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of the nurse intervention to obtain the mydriasis</measure>
    <time_frame>during 215 minutes maximum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of the dose of active drugs administrated</measure>
    <time_frame>one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and systemic clinical tolerance</measure>
    <time_frame>one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse reactions</measure>
    <time_frame>one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of a mydriasis of good quality at T+195</measure>
    <time_frame>at T+195 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Retinal Anomalies</condition>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Premature newborns and neonates treated using Phenylephrine and tropicamide eyedrops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Premature newborns and neonates treated using insert Mydriasert®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mydriasert®</intervention_name>
    <description>Premature newborns and neonates treated using ophthalmologic insert Mydriasert®</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phenylephrine and tropicamide eyedrops</intervention_name>
    <description>Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature newborns, neonates and infants of less 18 months-old indoor in the
             neonatology clinical department of Robert Debre Hospital with cardiologic monitoring

          -  Presenting a risk of retinopathy of prematurity or fundus anomaly (chorioretinal
             and/or disk anomalies).

          -  Needing a bilateral fundus

          -  Parents, tutor or legal representing of the patient had been informed of objectives of
             the study and had given their written consent.

          -  Covered by French social security or CMU

        Exclusion Criteria:

          -  Neonates of less 1000g at inclusion

          -  Premature newborn of less 30 weeks of gestational age at inclusion

          -  Contra-indication to one of the evaluated drugs

          -  Any treatment that could provoke a dangerous drug interaction for the patient if
             associated with one of the drug of the study

          -  Anatomical predisposition to glaucoma, hypertension or any other contra-indication
             noted by the physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique BREMOND GIGNAC, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Robert Debré, APHP, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>April 9, 2008</last_update_submitted>
  <last_update_submitted_qc>April 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mathieu QUINTIN</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>premature</keyword>
  <keyword>neonates</keyword>
  <keyword>infants</keyword>
  <keyword>children</keyword>
  <keyword>Mydriasert®</keyword>
  <keyword>mydriasis</keyword>
  <keyword>fundus</keyword>
  <keyword>Tropicamide</keyword>
  <keyword>Phenylephrine</keyword>
  <keyword>clinical trial</keyword>
  <keyword>Infant</keyword>
  <keyword>premature newborns</keyword>
  <keyword>bilateral diagnosis fundus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Tropicamide</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

